Citizens Reiterates Buy Rating for Mirum Pharmaceuticals, Inc.
Citizens maintains a buy rating for Mirum Pharmaceuticals with a $146 price target.
Key Points
- Citizens reiterated its buy rating for Mirum Pharmaceuticals, Inc. (MIRM) with a $146 price target on June 15, 2026.
- Shares of Mirum Pharmaceuticals traded near $99.35, with a market cap of $6.06 billion and a forward P/E ratio not meaningful due to lack of profitability.
- Notable institutional activity includes Frazier Life Sciences Management adding 884,563 shares, while State Street Corp reduced its position by 199,711 shares.
On June 15, 2026, Citizens reiterated its buy rating for Mirum Pharmaceuticals, Inc. (NasdaqGM: MIRM), maintaining a price target of $146. This reflects continued confidence in the biopharmaceutical company's prospects.
Other Institutional Activity in Mirum Pharmaceuticals
Several institutional investors have adjusted their positions in Mirum Pharmaceuticals recently. Frazier Life Sciences Management added 884,563 shares, raising its total to 7,679,684 shares valued at about $709.4 million. Janus Henderson Group also increased its holdings, adding 880,505 shares for a total of 6,945,813 shares worth approximately $641.8 million. BlackRock, Inc. boosted its position by 201,244 shares, bringing its total to 3,846,530 shares valued at $355.3 million. In contrast, State Street Corp reduced its stake by 199,711 shares, ending with 1,944,281 shares valued at $179.6 million.
Mirum Pharmaceuticals Stock Snapshot
Shares of Mirum Pharmaceuticals were trading around $99.35. The company's market cap stands at $6.06 billion. Despite its innovative therapies, Mirum is not yet profitable, resulting in no meaningful forward P/E ratio. The stock has a beta of 0.506, indicating lower volatility compared to the market. Over the past year, the stock has ranged from a low of $47.89 to a high of $114.99, with moving averages of $98.07 over 50 days and $85.59 over 200 days. Mirum maintains a solid current ratio of 2.087 and a quick ratio of 1.904, though it carries a debt-to-equity ratio of 133.52.
Recent Earnings
In its latest quarter, Mirum Pharmaceuticals reported revenue of $569.6 million, reflecting a growth rate of 43.3%. However, the company posted a net margin of -140.24% and a return on equity of -335.82%. The next earnings report is scheduled for August 5, 2026.
Insider Buying and Selling at Mirum Pharmaceuticals, Inc.
Recent insider activity includes notable transactions by Eric Bjerkholt, the Chief Financial Officer, who bought 2,393 shares at $26.49 on June 9, 2026. On the same day, he also sold 2,393 shares. Additionally, he sold 5,000 shares at an average price of $93.82 on June 8, 2026, under a Rule 10b5-1 plan. Peter Radovich, President and COO, acquired 16,988 shares at $19.19 on June 5, 2026.
Analysts Set New Price Targets
On June 15, 2026, Citizens maintained its buy rating for Mirum Pharmaceuticals with a target price of $146. Morgan Stanley also maintained a buy rating with a $150 target on June 11, 2026. Citigroup initiated coverage with a buy rating and a $145 target on June 2, 2026. The consensus among analysts is a strong buy, with an average target price of $144.93 based on 14 opinions.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a healthcare company based in Foster City, California, specializing in developing treatments for rare and orphan diseases. Its main product, LIVMARLI, treats Alagille syndrome, a rare liver disease. The company also markets Cholbam and Chenodal, which address bile acid disorders, and is developing Volixibat and other treatments for liver and viral diseases. Founded in 2018, Mirum is led by CEO Christopher Peetz and employs around 418 people.
Bottom Line
Citizens' reiteration of its buy rating for Mirum Pharmaceuticals highlights ongoing confidence in the company's pipeline and market position. While the 13F filings and insider transactions offer insight into institutional and executive sentiment, they reflect past actions and may not indicate future performance. Mirum's innovative treatments and market strategies continue to draw analyst attention.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.